Mirati Therapeutics, Inc. Stock, NASDAQ:MRTX
9393 Towne Centre Drive, Suite 200, San Diego, California 92121
United States of America
Number of Employees: 111
Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.